H.C. Wainwright lowered the firm’s price target on Cerevel Therapeutics to $45 from $48 and keeps a Buy rating on the shares. The company’s emracladine continues to advance "at full speed ahead," but other assets face modest delays, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CERE:
- Wells Fargo downgrades Cerevel on lack of catalysts until 2024
- Cerevel Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Cerevel Therapeutics reports Q4 EPS (59c), consensus (64c)
- Cerevel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
- Cerevel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates on Wednesday, February 22, 2023
